![Lilly's COVID-19 drug reduces death risk in patients on ventilator](https://static.foxnews.com/foxnews.com/content/uploads/2021/08/ventilator_istock.jpg)
Lilly's COVID-19 drug reduces death risk in patients on ventilator
Fox News
Eli Lilly and Co. said new data from a Phase 3 trial showed its COVID-19 drug, baricitinib, was shown to reduce deaths in patients receiving mechanical ventilation.
The study, which involved a cohort of 101 adult patients, found those on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who were given the drug and standard of care were 46% less likely to die by day 28 compared to those who received a placebo and standard of care. In the COV-BARRIER trial, 58% of patients in the placebo arm died by day 28, compared to 39.2% in the baricitinib group. By day 60, the proportion rose to 62% among the placebo arm, compared to 45.1% in the baricitinib group. No new safety signals were identified in either group.More Related News